BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

In December BPAX traded around $2.50 until efficacy results. If Bio-t-gel is approve and Libigel is back on track with a Cardiovascular Benefit expect to conservatively be trading north of $3.

Note: this price does not factor investor realization of worth of the cancer program. If this too is addressed in the conference you are possibly looking at $4 - $5 pps